When comparing the ACE inhibitor and ARB groups, mortality risk was lower in patients treated with ARBs (31.8% vs 51.0%; HR 0.85; 95% CI 0.76-0.95), with a nonsignificant trend toward less death due to aortic dissection or aneurysm (6.8% vs 11.5%; subdistribution HR 0.81; 95% CI 0.64...
The objective of this study was to compare the incidence of adverse events, medication discontinuation, or medication dose reduction in patients with HFrEF initiated on therapy with an ACE inhibitor, ARB, or sacubitril/valsartan.Methods A retrospective cohort study was conducted from July 7, 2015 ...
Using machine learning, we are able to identify patients who would benefit the most by receiving this type of medication. Our framework highlights the potential effect of this class of drugs for hypertensive patients or cases admitted with low oxygen saturation. By personalizing the drug prescription...
An aldosterone antagonist (AA) should be the drug of choice when adding a second renin-angiotensin-aldosterone system (RAAS) blocker to ACE inhibitors in patients with symptomatic systolic HF despite standard drug therapy, say the researchers behind a 16-trial meta-analysis [1]. Alone among the ...